Viridian Therapeutics, Inc.\de vs Wave Life Sciences
Viridian Therapeutics, Inc.\de is the larger business, with $70.8m of revenue in fiscal 2025 against $42.7m for Wave Life Sciences (1.7 times as much). Viridian Therapeutics, Inc.\de grew faster (23359.9% against -60.5%). Wave Life Sciences kept more of each dollar of sales as profit: a net margin of -478.3% against -483.6%.
| Latest fiscal year | Viridian Therapeutics, Inc.\deVRDN, 2025 | Wave Life SciencesWVE, 2025 |
|---|---|---|
| Revenue | $70.8m | $42.7m |
| Revenue growth | 23359.9% | -60.5% |
| Net income | −$343m | −$204m |
| Operating margin | -512.9% | — |
| Net margin | -483.6% | -478.3% |
| Return on equity | -49.2% | -56.2% |
| Free cash flow | −$277m | −$188m |
| Cash | $212m | $602m |
| Total debt | $49.9m | $0 |
| Debt to equity | 6.9% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 252 | 317 |
| Market value | $2.85bn | $707m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 1 buys, 3 sales | 6 buys, 46 sales |